GBT Stock Overview
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.
Price History & Performance
|Historical stock prices|
|Current Share Price||€24.85|
|52 Week High||€45.65|
|52 Week Low||€22.55|
|1 Month Change||0.61%|
|3 Month Change||-16.75%|
|1 Year Change||-21.73%|
|3 Year Change||-48.07%|
|5 Year Change||-70.02%|
|Change since IPO||150.14%|
Recent News & Updates
Analysts Have Been Trimming Their Guerbet SA (EPA:GBT) Price Target After Its Latest Report
Guerbet SA ( EPA:GBT ) shareholders are probably feeling a little disappointed, since its shares fell 9.1% to €26.50 in...
Is Guerbet (EPA:GBT) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
|GBT||FR Medical Equipment||FR Market|
Return vs Industry: GBT underperformed the French Medical Equipment industry which returned -5.8% over the past year.
Return vs Market: GBT underperformed the French Market which returned -5.9% over the past year.
|GBT Average Weekly Movement||5.1%|
|Medical Equipment Industry Average Movement||7.0%|
|Market Average Movement||5.9%|
|10% most volatile stocks in FR Market||10.0%|
|10% least volatile stocks in FR Market||3.4%|
Stable Share Price: GBT is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: GBT's weekly volatility (5%) has been stable over the past year.
About the Company
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate; Conray, an othalamate meglumine injection; and Micropaque/ Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem products, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain that offers cloud-based AI solutions, as well as OptiProtect services.
Guerbet Fundamentals Summary
|GBT fundamental statistics|
Is GBT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GBT income statement (TTM)|
|Cost of Revenue||€190.90m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Sep 21, 2022
|Earnings per share (EPS)||2.59|
|Net Profit Margin||4.42%|
How did GBT perform over the long term?See historical performance and comparison
3.4%Current Dividend Yield
Does GBT pay a reliable dividends?See GBT dividend history and benchmarks
|Guerbet dividend dates|
|Ex Dividend Date||Jun 29 2022|
|Dividend Pay Date||Jul 01 2022|
|Days until Ex dividend||33 days|
|Days until Dividend pay date||35 days|
Does GBT pay a reliable dividends?See GBT dividend history and benchmarks
Is Guerbet undervalued compared to its fair value and its price relative to the market?
Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GBT (€24.85) is trading below our estimate of fair value (€61.33)
Significantly Below Fair Value: GBT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: GBT is good value based on its Price-To-Earnings Ratio (9.6x) compared to the French Medical Equipment industry average (13.7x).
PE vs Market: GBT is good value based on its Price-To-Earnings Ratio (9.6x) compared to the French market (16.2x).
Price to Earnings Growth Ratio
PEG Ratio: GBT is poor value based on its PEG Ratio (1.1x)
Price to Book Ratio
PB vs Industry: GBT is good value based on its Price-To-Book Ratio (0.8x) compared to the FR Medical Equipment industry average (2.2x).
How is Guerbet forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GBT's forecast earnings growth (8.6% per year) is above the savings rate (0.3%).
Earnings vs Market: GBT's earnings (8.6% per year) are forecast to grow slower than the French market (11.9% per year).
High Growth Earnings: GBT's earnings are forecast to grow, but not significantly.
Revenue vs Market: GBT's revenue (4.7% per year) is forecast to grow slower than the French market (5.8% per year).
High Growth Revenue: GBT's revenue (4.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GBT's Return on Equity is forecast to be low in 3 years time (9.4%).
How has Guerbet performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GBT has high quality earnings.
Growing Profit Margin: GBT's current net profit margins (4.4%) are higher than last year (2.5%).
Past Earnings Growth Analysis
Earnings Trend: GBT's earnings have declined by 8.4% per year over the past 5 years.
Accelerating Growth: GBT's earnings growth over the past year (84%) exceeds its 5-year average (-8.4% per year).
Earnings vs Industry: GBT earnings growth over the past year (84%) exceeded the Medical Equipment industry 22.5%.
Return on Equity
High ROE: GBT's Return on Equity (8%) is considered low.
How is Guerbet's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: GBT's short term assets (€496.0M) exceed its short term liabilities (€237.0M).
Long Term Liabilities: GBT's short term assets (€496.0M) exceed its long term liabilities (€359.0M).
Debt to Equity History and Analysis
Debt Level: GBT's net debt to equity ratio (53.8%) is considered high.
Reducing Debt: GBT's debt to equity ratio has reduced from 125.6% to 82.5% over the past 5 years.
Debt Coverage: GBT's debt is well covered by operating cash flow (30.8%).
Interest Coverage: GBT's interest payments on its debt are well covered by EBIT (14x coverage).
What is Guerbet current dividend yield, its reliability and sustainability?
Dividend Score 5/6
Future Dividend Coverage
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: GBT's dividend (3.42%) is higher than the bottom 25% of dividend payers in the French market (1.72%).
High Dividend: GBT's dividend (3.42%) is low compared to the top 25% of dividend payers in the French market (5.01%).
Stability and Growth of Payments
Stable Dividend: GBT's dividends per share have been stable in the past 10 years.
Growing Dividend: GBT's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (32.5%), GBT's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Insufficient data to calculate cash payout ratio to determine if its dividend payments are covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
David Hale (53 yo)
Mr. David Hale has been Chief Executive Officer of Guerbet SA since January 1, 2020 and serves as its MD & GM. Mr. Hale served as Chief Commercial Officer of Guerbet SA since 2019 until January 1, 2020 and...
CEO Compensation Analysis
Compensation vs Market: David's total compensation ($USD1.00M) is above average for companies of similar size in the French market ($USD479.65K).
Compensation vs Earnings: Insufficient data to compare David's compensation with company performance.
Experienced Management: GBT's management team is considered experienced (2.3 years average tenure).
Experienced Board: GBT's board of directors are considered experienced (6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Guerbet SA's employee growth, exchange listings and data sources
- Name: Guerbet SA
- Ticker: GBT
- Exchange: ENXTPA
- Founded: 1926
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: €313.009m
- Shares outstanding: 12.60m
- Website: https://www.guerbet.com
Number of Employees
- Guerbet SA
- 15, rue des Vanesses
- Zone Paris Nord II
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/26 00:00|
|End of Day Share Price||2022/05/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.